Molecular pathogenesis of T-cell leukaemia and lymphoma

Nature Reviews Immunology

Volumn 8, Issue 5, 2008, Pages 380-390

  Aifantis, Iannis ^a   Raetz, Elizabeth ^a   Buonamici, Silvia ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; HELIX LOOP HELIX PROTEIN; HOMEODOMAIN PROTEIN; NOTCH1 RECEPTOR; T LYMPHOCYTE RECEPTOR;

CHROMOSOME ABERRATION; HEMATOPOIESIS; HOMEOBOX; HUMAN; IN SITU HYBRIDIZATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE TRANSFORMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T CELL LYMPHOMA; UBIQUITINATION;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINEAGE; CHILD; F-BOX PROTEINS; GENE EXPRESSION REGULATION, LEUKEMIC; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOMA; MICE; MUTATION; NF-KAPPA B; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THYMUS GLAND; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 42649124306     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2304     Document Type: Review

References (101)

1. Uckun, F. M. et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J. Clin. Oncol. 15, 2214-2221 (1997).
2. Crist, W. M. et al. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. Blood 72, 1891-1897 (1988).
3. Graux, C., Cools, J., Michaux, L., Vandenberghe, P. & Hagemeijer, A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia 20, 1496-1510 (2006).
4. Clappier, E. et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 110, 1251-1261 (2007).
5. Lahortiga, I. et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nature Genet. 39, 593-595 (2007).
6. O'Neil, J. et al. Alu elements mediate MYB gene tandem duplication in human T-ALL. J. Exp. Med. (2007).
7. Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004).
8. Akashi, K., Reya, T., Dalma-Weiszhausz, D. & Weissman, I. L. Lymphoid precursors. Curr. Opin. Immunol. 12, 144-150 (2000).
9. Petrie, H. T. & Zúñiga-Pflücker, J. C. Zoned out: functional mapping of stromal signaling microenvironments in the thymus. Annu. Rev. Immunol. 25, 649-679 (2007).
10. Scimone, M. L., Aifantis, I., Apostolou, I., von Boehmer, H. & von Andrian, U. H. A multistep adhesion cascade for lymphoid progenitor cell homing to the thymus. Proc. Natl Acad. Sci. USA 103, 7006-7011 (2006).
11. Von Boehmer, H. et al. Thymic selection revisited: how essential is it? Immunol. Rev. 191, 62-78 (2003).
12. Di Santo, J. P., Radtke, F. & Rodewald, H. R. To be or not to be a pro-T? Curr. Opin. Immunol. 12, 159-165 (2000).
13. El Andaloussi, A. et al. Hedgehog signaling controls thymocyte progenitor homeostasis and differentiation in the thymus. Nature Immunol. 7, 418-426 (2006).
14. Artavanis-Tsakonas, S. The molecular biology of the Notch locus and the fine tuning of differentiation in Drosophila. Trends Genet. 4, 95-100 (1988).
15. Ilagan, M. X. & Kopan, R. SnapShot: notch signaling pathway. Cell 128, 1246 (2007).
16. Barrick, D. & Kopan, R. The Notch transcription activation complex makes its move. Cell 124, 883-885 (2006). This Review summarizes the papers that described for the first time the crystal structure of a Notch-CSL-MAML1 complex.
17. Ellisen, L. W. et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661 (1991).
18. Robey, E. et al. An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 87, 483-492 (1996).
19. Radtke, F. et al. Notch1 deficiency dissociates the intrathymic development of dendritic cells and T cells. J. Exp. Med. 191, 1085-1094 (2000).
20. Pui, J. C. et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11, 299-308 (1999).
21. Maillard, I. & Pear, W. S. Immunology. Keeping a tight leash on Notch. Science 316, 840-842 (2007).
22. Ciofani, M. & Zúñiga-Pflücker, J. C. Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism. Nature Immunol. 6, 881-888 (2005).
23. Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261-18266 (2006).
24. Maillard, I. et al. The requirement for Notch signaling at the β-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor. J. Exp. Med. 203, 2239-2245 (2006).
25. Borowski, C. et al. On the brink of becoming a T cell. Curr. Opin. Immunol. 14, 200-206 (2002).
26. Yokosuka, T. et al. Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76. Nature Immunol. 6, 1253-1262 (2005).
27. Ciofani, M. et al. Obligatory role for cooperative signaling by pre-TCR and Notch during thymocyte differentiation. J. Immunol. 172, 5230-5239 (2004).
28. Wolfer, A., Wilson, A., Nemir, M., MacDonald, H. R. & Radtke, F. Inactivation of Notch1 impairs VDJβ rearrangement and allows pre-TCR-independent survival of early αβ lineage thymocytes. Immunity 16, 869-879 (2002).
29. Aifantis, I., Mandal, M., Sawai, K., Ferrando, A. & Vilimas, T. Regulation of T-cell progenitor survival and cell-cycle entry by the pre-T-cell receptor. Immunol. Rev. 209, 159-169 (2006).
30. Reschly, E. J. et al. Notch1 promotes survival of E2A-deficient T cell lymphomas through Pre-T cell receptor dependent and independent mechanisms. Blood 107, 4115-4121 (2006).
31. Reizis, B. & Leder, P. Direct induction of T lymphocyte-specific gene expression by the mammalian Notch signaling pathway. Genes Dev. 16, 295-300 (2002).
32. Allman, D. et al. Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells. J. Exp. Med. 194, 99-106 (2001).
33. Vilimas, T. et al. Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia. Nature Med. 13, 70-77 (2007). This report shows that the NF-κB pathway is a downstream target of Notch1 activation. It also suggests that drugs that affect NF-βB activation, including the proteasome inhibitor Velcade could be useful in T-ALL therapy.
34. 2+ mobilization and activation of NF-κB and NFAT. Nature Immunol. 2, 403-409 (2001).
35. Medyouf, H. et al. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nature Med. 13, 736-741 (2007). This report identifies a potential role for the calcineurin-NFAT signalling pathway in T-cell leukaemia and suggests that drugs that target this pathway could affect disease progression.
36. Sicinska, E. et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-461 (2003).
37. Mandal, M. et al. The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. J. Exp. Med. 201, 603-614 (2005).
38. Grabher, C., von Boehmer, H. & Look, A. T. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nature Rev. Cancer 5, 347-359 (2006).
39. Carroll, A. J. et al. The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 76, 1220-1224 (1990).
40. Brown, L. et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J. 9, 3343-3351 (1990).
41. Janssen, J. W., Ludwig, W. D., Sterry, W. & Bartram, C.R. SIL-TAL1 deletion in T-cell acute lymphoblastic leukemia. Leukemia 7, 1204-1210 (1993).
42. Curtis, D. J., Robb, L., Strasser, A. & Begley, C. G. The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice. Oncogene 15, 2975-2983 (1997).
43. Elwood, N. J. & Begley, C. G. Reconstitution of mice with bone marrow cells expressing the SCL gene is insufficient to cause leukemia. Cell Growth Differ. 6, 19-25 (1995).
44. Kelliher, M. A., Seldin, D. C. & Leder, P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIα. EMBO J. 15, 5160-5166 (1996).
45. Larson, R. C. et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 15, 1021-1027 (1996).
46. Aplan, P. D. et al. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J. 16, 2408-2419 (1997).
47. Chervinsky, D. S., Lam, D. H., Melman, M. P., Gross, K. W. & Aplan, P. D. Scid thymocytes with TCRβ gene rearrangements are targets for the oncogenic effect of SCL and LMO1 transgenes. Cancer Res. 61, 6382-6387 (2001).
48. Chervinsky, D. S., Lam, D. H., Zhao, X. F., Melman, M. P. & Aplan, P. D. Development and characterization of T cell leukemia cell lines established from SCL/LMO1 double transgenic mice. Leukemia 15, 141-147 (2001).
49. Chervinsky, D. S. et al. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol. Cell Biol. 19, 5025-5035 (1999).
50. Virgilio, L. et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc. Natl Acad. Sci. USA 95, 3885-3889 (1998).
51. Condorelli, G. L. et al. T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res. 56, 5113-5119 (1996).
52. Fasseu, M. et al. p16INK4A tumor suppressor gene expression and CD3ε deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis. Blood 110, 2610-2619 (2007).
53. Shank-Calvo, J. A., Draheim, K., Bhasin, M. & Kelliher, M. A. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Oncogene 25, 3023-3031 (2006).
54. Ono, Y., Fukuhara, N. & Yoshie, O. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL. J. Biol. Chem. 272, 4576-4581 (1997).
55. + transition. Neoplasia 9, 315-321 (2007).
56. Voronova, A. F. & Lee, F. The E2A and tal-1 helix-loop-helix proteins associate in vivo and are modulated by Id proteins during interleukin 6-induced myeloid differentiation. Proc. Natl Acad. Sci. USA 91, 5952-5956 (1994).
57. Hsu, H. L., Cheng, J. T., Chen, Q. & Baer, R. Enhancer-binding activity of the tal-1 oncoprotein in association with the E47/E12 helix-loop-helix proteins. Mol. Cell Biol. 11, 3037-3042 (1991).
58. Hsu, H. L., Wadman, I. & Baer, R. Formation of in vivo complexes between the TAL1 and E2A polypeptides of leukemic T cells. Proc. Natl Acad. Sci. USA 91, 3181-3185 (1994).
59. Park, S. T. & Sun, X. H. The Tal1 oncoprotein inhibits E47-mediated transcription. Mechanism of inhibition. J. Biol. Chem. 273, 7030-7037 (1998).
60. O'Neil, J., Shank, J., Cusson, N., Murre, C. & Kelliher, M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5, 587-596 (2004).
61. Palomero, T. et al. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia. Blood 108, 986-992 (2006).
62. Mellentin, J. D., Smith, S. D. & Cleary, M. L. lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 58, 77-83 (1989).
63. Giroux, S. et al. lyl-1 and tal-1/scl, two genes encoding closely related bHLH transcription factors, display highly overlapping expression patterns during cardiovascular and hematopoietic ontogeny. Gene Expr. Patterns 7, 215-226 (2007).
64. Zhong, Y., Jiang, L., Hiai, H., Toyokuni, S. & Yamada, Y. Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice. Oncogene 26, 6937-6947 (2007).
65. Meng, Y. S., Khoury, H., Dick, J. E. & Minden, M. D. Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. Leukemia 19, 1941-1947 (2005).
66. Boehm, T. et al. The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor Cδ locus on human chromosome 14q11 and a transcribed region of chromosome 11p15. EMBO J. 7, 385-394 (1988).
67. Boehm, T., Foroni, L., Kaneko, Y., Perutz, M. F. & Rabbitts, T. H. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc. Natl Acad. Sci. USA 88, 4367-4371 (1991).
68. Royer-Pokora, B., Loos, U. & Ludwig, W. D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6, 1887-1893 (1991).
69. Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
70. Wadman, I. A. et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 16, 3145-3157 (1997).
71. Valge-Archer, V., Forster, A. & Rabbitts, T. H. The LMO1 and LDB1 proteins interact in human T cell acute leukaemia with the chromosomal translocation t(11;14)(p15;q11). Oncogene 17, 3199-3202 (1998).
72. Valge-Archer, V. E. et al. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc. Natl Acad. Sci. USA 91, 8617-8621 (1994).
73. Osada, H., Grutz, G., Axelson, H., Forster, A. & Rabbitts, T. H. Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc. Natl Acad. Sci. USA 92, 9585-9589 (1995).
74. Grutz, G. G. et al. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J. 17, 4594-4605 (1998).
75. Owens, B. M. & Hawley, R. G. HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells 20, 364-379 (2002).
76. Gehring, W. J. et al. Homeodomain-DNA recognition. Cell 78, 211-223 (1994).
77. Soulier, J. et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood 106, 274-286 (2005).
78. Speleman, F. et al. A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia 19, 358-366 (2005).
79. Look, A. T. Oncogenic transcription factors in the human acute leukemias. Science 278, 1059-1064 (1997).
80. Roberts, C. W., Shutter, J. R. & Korsmeyer, S. J. Hox11 controls the genesis of the spleen. Nature 368, 747-749 (1994).
81. Su, X. et al. Transforming potential of the T-cell acute lymphoblastic leukemia-associated homeobox genes HOXA13, TLX1, and TLX3. Genes Chromosomes Cancer 45, 846-855 (2006).
82. Hawley, R. G., Fong, A. Z., Lu, M. & Hawley, T. S. The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene 9, 1-12 (1994).
83. Hawley, R. G. et al. Transforming function of the HOX11/TCL3 homeobox gene. Cancer Res. 57, 337-345 (1997).
84. Dixon, D. N. et al. TLX1/HOX11 transcription factor inhibits differentiation and promotes a non-haemopoietic phenotype in murine bone marrow cells. Br. J. Haematol. 138, 54-67 (2007).
85. Pear, W. S. et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 183, 2283-2291 (1996).
86. Rohn, J. L., Lauring, A. S., Linenberger, M. L. & Overbaugh, J. Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma. J. Virol. 70, 8071-8080 (1996).
87. Bellavia, D. et al. Constitutive activation of NF-κB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J. 19, 3337-3348 (2000).
88. Bellavia, D. et al. Combined expression of pTα and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc. Natl Acad. Sci. USA 99, 3788-3793 (2002).
89. Malecki, M. J. et al. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol. Cell Biol. 26, 4642-4651 (2006).
90. Ferrando, A. A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75-87 (2002).
91. Klinakis, A. et al. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc. Natl Acad. Sci. USA 103, 9262-9267 (2006).
92. Weng, A. P. et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 20, 2096-2109 (2006).
93. Sharma, V. M. et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol. Cell Biol. 26, 8022-8031 (2006). These three reports (references 91-93) together with Palomero et al. (reference 23) demonstrate that MYC is a direct transcriptional target of Notch1 in T-ALL and breast cancer.
94. Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Med. 13, 1203-1210 (2007). This report identifies PTEN mutations in patients with T-ALL and connects them to resistance to γ-secretase inhibitors.
95. Gupta-Rossi, N. et al. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J. Biol. Chem. 276, 34371-34378 (2001).
96. Hubbard, E. J., Wu, G., Kitajewski, J. & Greenwald, I. sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes Dev. 11, 3182-3193 (1997).
97. Tetzlaff, M. T. et al. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc. Natl Acad. Sci. USA 101, 3338-3345 (2004).
98. O'Neil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007).
99. Thompson, B. J. et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835 (2007).
100. Maser, R. S. et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966-971 (2007). References 98-100 are the first to show that FBW7 is an E3 ubiquitin ligase specific for oncogenic Notch1 and identify FBW7 inactivating mutations in T-ALL patients.
101. Onoyama, I. et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 204, 2875-2888 (2007).